<DOC>
	<DOCNO>NCT03056326</DOCNO>
	<brief_summary>Human Neutrophil Elastase ( HNE ) play pivotal role innate immunity neutrophilic lung inflammation characterize many disease . CHF 6333 potent 24h-durable inhibitor HNE , develop Dry Powder Inhaler ( DPI ) formulation . This study design investigate tolerability , safety pharmacokinetics inhale CHF6333 DPI healthy male subject . The study comprise two part : Part 1 consist two alternated cohort healthy male subject assess safety , tolerability pharmacokinetics Single Ascending Dose ( SAD ) CHF6333 . Part 2 consist four sequential cohort healthy male subject assess safety , tolerability pharmacokinetics Multiple Ascending Dose ( MAD ) CHF6333</brief_summary>
	<brief_title>A Study Investigate Safety , Tolerability Pharmacokinetics Single Repeat Doses CHF6333 Healthy Subjects</brief_title>
	<detailed_description />
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Cystic Fibrosis</mesh_term>
	<mesh_term>Bronchiectasis</mesh_term>
	<criteria>Male subject age 1855 year BMI 1830 kg/m2 Non smoker Lung function 80 % predict normal value Healthy subject base medical evaluation include medical history , physical examination , laboratory test cardiac test Any clinically relevant abnormality and/or uncontrolled disease Abnormal laboratory value Recent respiratory tract infection Hypersensitivity drug excipients Positive serology result Positive cotinine , alcohol , drug abuse test Unsuitable vein repeat venepuncture</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>